Seven-day supplementation with piceatannol does not improve endothelial function at rest or after exercise: a pilot study Authors: Nobukazu Kasai, Kanon Hayashi, Masaki Kito, Takuma Morishima Published: 2025 ABSTRACT [Purpose]Piceatannol, a polyphenolic compound found in high concentrations in passion fruit, has been reported to exert multiple physiological effects in preclinical studies, including vascular relaxation and increased expression of endothelial nitric oxide synthase. Despite these findings, its influence on endothelial function in humans, both at rest and in response to exercise, remains largely unknown. Therefore, this study aimed to investigate whether a 7-day regimen of piceatannol supplementation alters endothelial function at rest and following low-intensity aerobic exercise.[Methods]Eight young, healthy men participated in a randomized, double-blind, crossover trial. Each participant completed two experimental conditions: (1) a placebo trial and (2) a piceatannol trial. For seven consecutive days, they ingested tablets containing either 0 mg (placebo) or 10 mg of piceatannol daily. On the morning of the eighth day (8:00 am), they visited the laboratory for baseline assessments, followed by 60 minutes of cycling exercise at 30% of their maximal oxygen uptake. Blood pressure and brachial artery flow-mediated dilation (FMD) were measured before and after exercise.[Results]No between-trial differences were observed in blood pressure at rest, during exercise, or after exercise. %FMD and absolute FMD likewise did not differ between the placebo and piceatannol trials. The observed effects were small (partial η² ≈ 0.05-0.06), and analysis of covariance adjusting for baseline diameter or shear rate area under the curve yielded consistent results.[Conclusion]Seven-day piceatannol supplementation did not enhance endothelial function at rest or after low-intensity aerobic exercise in young, healthy men. INTRODUCTION Cardiovascular disease has become increasingly prevalent and is primarily driven by lifestyle factors [1-3]. Focusing on vascular endothelial function is essential for the prevention of cardiovascular diseases. Among the early indicators of cardiovascular disease development, endothelial dysfunction is recognized as a key vascular abnormality and a predictor of atherosclerosis onset [4,5]. It is strongly associated with the risk of cardiovascular diseases [4,5]. Polyphenols have been widely studied for their potential health benefits and as a nutritional strategy for the prevention of cardiovascular disease, particularly because they protect cells from oxidative stress [6]. Evidence suggests that polyphenols can positively affect energy metabolism, which promotes longevity and overall mortality [7]. Polyphenols also exert beneficial effects on cardiovascular health by improving endothelial function [8], reducing blood pressure [9], and inhibiting the oxidation of low-density lipoprotein cholesterol [10]. Mechanistically, dietary polyphenols can augment endothelial nitric oxide (NO) bioavailability and attenuate vasoconstrictor/inflammatory pathways, providing a plausible basis for vascular protection. Consistent with these mechanisms, human interventions with polyphenol-rich foods have shown acute and short-term improvements in endothelial function [8]. Recently, piceatannol, which is a type of polyphenol, has garnered interest as a medicinal supplement. It is an abundant natural phenolic compound in passion fruit and is also known as 3,3′,4,5′-trans-tetrahydroxy- stilbene or trans-3,4′,5′-tetrahydroxy-stilbene [11]. Piceatannol has various therapeutic effects, such as the prevention of hypercholesterolemia, angiogenesis, and vasorelaxation, as well as anticancer, anti-inflammatory, and antioxidant activities [12,13]. Moreover, isorhapontigenin upregulates the sirtuin 1 (SIRT1) expression [14] and endothelial nitric oxide synthase (eNOS) [15]. Polyphenols have the potential to improve vascular function by promoting eNOS activity and enhancing NO bioavailability [16,17]. Piceatannol induces endothelium-dependent acute vasorelaxation in the rat thoracic aorta [18]. Therefore, it may represent a novel nutritional strategy to prevent cardiovascular disease. However, its effect on humans is limited as most findings have been reported from preclinical (in vitro and animal models) studies. Although human evidence is limited, prior work in humans has shown no detectable improvement in resting endothelial function with piceatannol supplementation [19]. This highlights the need for further investigation. Notably, human interventions with the stilbene resveratrol have reported acute or short-term improvements in endothelial function [8], underscoring a class-level signal while human data on piceatannol remain limited. Aerobic exercise reduces the risk of vascular diseases by improving endothelial function [20-22]. Regular aerobic activity promotes the release of NO, which enhances vasodilation and improves endothelial-dependent vasomotor function [23]. During acute aerobic exercise, an exercise-induced increase in the shear rate stimulates endothelial-dependent NO production and, consequently, vasodilatation [24,25]. However, moderate-to-high-intensity exercise, often prescribed for these benefits [26], may not be feasible for individuals with low physical fitness or chronic conditions and poses adherence challenges. Therefore, it is now important to investigate the role of low-intensity aerobic exercise in promoting vascular health. Even light-to-moderate exercise can enhance endothelial function by increasing NO bioavailability and reducing oxidative stress [27]. While preclinical studies suggest that piceatannol can favorably influence endothelial pathways, human data remain scarce, and a study has reported no improvement in resting endothelial function with piceatannol supplementation [19]. In light of this gap, and given that aerobic exercise provides a physiological shear-stress stimulus to the endothelium, we examined whether combining short-term piceatannol supplementation with aerobic exercise could yield additive or synergistic effects on vascular function. Consistent with this rationale, previous study indicates that nutritional supplementation can augment the acute vascular response to exercise. For example, short-term dietary nitrate (beetroot juice) supplementation has been reported to improve endothelial function after aerobic exercise [28]. However, to date, no studies have investigated the combined effects of piceatannol supplementation and exercise on vascular endothelial function. The present study was designed to determine the effect of seven consecutive days of piceatannol ingestion on endothelial function at rest and after low-intensity aerobic exercise in young, healthy men. Preclinical evidence indicates that piceatannol and its metabolite isorhapontigenin can upregulate SIRT1, activate eNOS, and increase NO bioavailability [15-18]. Because conduit-artery endothelial function in humans is NO-mediated and sensitive to shear-induced endothelial signaling, these mechanisms provide a directly translatable pathway to human vascular function. Accordingly, we hypothesized that 7-day piceatannol supplementation would augment the acute endothelial response to aerobic exercise compared with placebo. METHODS Participants Eight healthy male subjects participated in the study [mean ± standard deviation (SD): age, 20.2 ± 1.6 years; height, 175.5 ± 6.1 cm; body weight (BW), 65.6 ± 5.1 kg; body mass index (BMI), 21.2 ± 1.3 kg/m2]. All individuals enrolled in the study were healthy, nonsmoking adults with no prior diagnosis or current symptoms related to cardiovascular, respiratory, metabolic, or neurological conditions. None of the participants were using any form of medication at the time of the study. Participants maintained their habitual diet and physical activity; no standardized meals or activity logs were implemented. They avoided nutritional supplements and polyphenol-rich foods throughout the experimental period. Prior to participation, all subjects received detailed information about the study procedures and potential risks, and gave written informed consent. The research protocol adhered to the ethical standards outlined in the Declaration of Helsinki and received approval from the Human Research Ethics Committee of Human Research Ethics Committee of Chukyo University. (Approval ID: 2024-004). This study is part of a broader investigation. Related findings focusing on metabolic responses have been reported elsewhere [29]. Study design This investigation employed a randomized, double-blind, crossover design. Each participant completed two distinct experimental conditions: (1) a placebo condition and (2) a piceatannol condition. The sequence of these trials was randomized, with a minimum washout period of 14 days between sessions. In total, participants attended the laboratory on three separate occasions during the study period. At the first visit, they underwent a graded exercise test using a cycle ergometer (Aerobike 75XLIII; Konami Corporation, Tokyo, Japan) to determine maximal oxygen uptake (V˙O2max). The protocol commenced at 50 W, with incremental increases of 30 W every 2 minutes at a pedaling cadence of 70 rpm. The test was discontinued if the participant’s cadence dropped below 70 rpm for more than 5 seconds (indicating exhaustion), or if a plateau in oxygen consumption (V˙O2) was observed. Respiratory gases were measured using an automated gas analysis system (AE300S; Minato Medical Science Co., Ltd., Tokyo, Japan), and data were averaged over 30-second intervals. V˙O2max was defined as the highest recorded V˙O2 value during the exercise. Following the initial exercise test, the participants ingested either a placebo or piceatannol tablets for seven consecutive days. After seven days (i.e., day 8), they visited the laboratory between 8:00 am to 10:00 am (visits 2 and 3) to undergo the experimental trials. All experimental trials were performed after an overnight fast (at least 10 h). The participants were asked to refrain from caffeine and alcohol for at least 10 h as well as from exercise for 24 h before the study visits. Approximately two weeks after the preliminary experiments for the incremental pedaling test, the main experiment was conducted. Dietary intervention The participants consumed Passional® capsules (10 mg/day of supplemented piceatannol) or placebo capsules (0 mg/day of supplemented piceatannol) for seven days. The subjects consumed four capsules with every breakfast meal in each condition. The capsules were taste-matched and appeared the same. The dosage and 7-day intervention period were determined with reference to a previous study conducted in Japan, which demonstrated physiological effects of piceatannol following short-term supplementation [30]. The nutritional composition by weight percentage was as follows: carbohydrate 79.2%, protein 6.6%, fat 4.8%, vitamin C 7.9%, niacin 1.3%, and salt equivalent 0.2% (piceatannol trial.). The placebo capsules were formulated using Placeplus®200 (Placebo Pharmaceutical Co., Ltd., Japan), a commercially available food-grade filler. The ingredient composition by weight percentage was as follows: carbohydrate (maltitol) 96.0%, cellulose 2.0%, calcium stearate 1.0%, and silicon dioxide 1.0%. Both the piceatannol and placebo capsules were packaged in unlabeled, transparent plastic pouches and administered by a researcher who was not involved in data collection or analysis. Randomization and blinding procedures were managed by an independent researcher, and the allocation code was concealed until the completion of all data collection. Compliance was assessed based on the number of unused capsules returned at the end of each intervention period. Experimental trial Figure 1 illustrates a schematic of the experimental trial. Upon arrival at the laboratory, verbal confirmation was obtained to ensure compliance with the pre-test instructions, including fasting and avoidance of caffeine. Following a 10-minute supine rest, blood pressure and heart rate HR were measured with an automated sphygmomanometer (HEM-8712, Omron Corp., Kyoto, Japan) and a wearable HR monitor (VANTAGE M2; Polar), respectively. In this study, flow-mediated dilation (FMD) was measured as an index of vascular endothelial function. For this assessment, imaging of the right brachial artery was performed using a duplex Doppler ultrasound system (LOGIQe; GE Healthcare, WI, USA) that continuously captured arterial diameter and blood flow velocity. A 10-MHz transducer was positioned carefully on the artery with reference markers to ensure reproducibility between sessions. Duplex mode allowed simultaneous acquisition of diameter and velocity at a pulsed frequency of 30 MHz, with insonation corrected to a 60° angle. All procedures followed best-practice guidelines for FMD assessment [31]. Data analysis was performed by an experienced examiner who remained blinded to the study conditions. Further technical details regarding the ultrasound procedures, hemodynamic assessments, and brachial artery FMD protocols have been previously described [32-34]. Briefly, a rapidly inflating cuff was placed on the forearm, baseline values were collected for 2 minutes, and the cuff was inflated to 220 mmHg for 5 minutes. Continuous measurements of arterial diameter and blood velocity were obtained for 3 minutes after cuff release. All vascular recordings were analyzed offline using specialized edge-detection software (Cardiovascular Suite; Quipu srl., Pisa, Italy). The coefficient of variation of the baseline brachial artery FMD was 5.0%. After baseline assessments, participants completed 60 minutes of steady-state exercise on an electromagnetically braked cycle ergometer (Fujin-raijin; OCL Co., Ltd., Tokyo, Japan) at an intensity corresponding to 30% of their V˙O2max. We set the exercise intensity at 30% V˙O2max to provide a mild aerobic workload that can be safely sustained for 60 minutes. Our aim was to examine whether a low shear-stress stimulus, in combination with piceatannol supplementation, could enhance endothelial function. During exercise, HR was continuously recorded and blood pressure was assessed every 15 minutes using the same devices, respectively. Immediately following the exercise session, participants were placed back in the supine position, and measurements of blood pressure, HR, and FMD were repeated at 10, 30, and 60 minutes post-exercise. Data analysis Blood flow was estimated based on arterial diameter and mean velocity: 3.14 × (diameter/2)2 × mean blood velocity × 60. To quantify vascular responsiveness, we computed FMD (%) based on peak-to-basal diameter changes, using a standard equation: %FMD = (peak diameter - base diameter) / (base diameter) × 100. Shear rate, which serves as an index of shear stress in the absence of blood viscosity data, was calculated using the equation: 4 × mean blood velocity / diameter. To evaluate the stimulus for FMD, the area under the shear rate curve [35] from the time of cuff release until the artery reached its peak diameter was computed, following established methods [33,36]. Statistical analysis All variables except FMD are reported as mean, SD, and 95% CI. FMD data are presented as mean ± SD. Statistical analyses were conducted using SPSS for Windows (Version 24.0; SPSS Inc., Tokyo, Japan). No formal a priori sample-size calculation was performed. The final sample size was 8. Sensitivity analyses were performed in G*Power 3.1 (α = 0.05). A two-way repeated-measures analysis of variance (ANOVA) was employed to examine the interaction between time and trial as well as the main effects of each factor. When significant interactions or main effects were identified, post hoc comparisons were carried out using the Tukey-Kramer test (sensitivity: minimal detectable interaction f = 0.359; partial η2 ≈ 0.114; n = 8; assumed correlation among repeated measures = 0.50; ε = 1.0). Furthermore, FMD values were analyzed using analysis of covariance (ANCOVA) with basal arterial diameter and hyperemic shear rate AUC as covariates to account for their influence on the %FMD response. Sensitivity analysis (2×4 repeated measures; α = 0.05; power = 0.80; n = 8) indicated that with Rcov2 = 0.288 for these covariates, the ANCOVA-adjusted minimum detectable interaction is f ≈ 0.303 (corresponding to partial η2 ≈ 0.084). The ΔFMD between trials was compared using the paired t-test. Statistical significance was set at p < 0.05 for all analyses. RESULTS Systolic blood pressure and HR significantly increased with exercise (p < 0.05); however, no significant differences were observed between the trials in their responses. Diastolic blood pressure did not significantly change throughout the experimental period in both trials (Table 1). Basal and peak diameters, shear rate and blood flow showed no main effect of trial or trial × time interaction, while a significant main effect of time was observed, suggesting a temporal tendency irrespective of trial. Shear rate AUC showed no significant main effect of trial or trial × time interaction. The main effect of time was also not significant, though the effect size (partial ηp² = 0.22) indicated a small-to-moderate temporal trend irrespective of trial (Table 2). Although neither absolute nor relative FMD showed statistically significant trial or interaction effects, both parameters exhibited small-to-moderate effect sizes (partial ηp² ≈ 0.05-.19). These values may reflect minor but consistent physiological changes in endothelial function over time, regardless of the trial condition (Figure 2 and 3). For ΔFMD relative to pre, none of the post-time points reached statistical significance. ANCOVA adjusted for basal diameter and shear rate AUC revealed no significant main effects of trial, time, or their interaction. These results indicate that adjusting for baseline diameter or shear rate AUC did not alter the pattern of FMD responses across trials or time points (Table 2). DISCUSSION In this study, a 7-day supplementation of piceatannol did not improve endothelial function at rest or after low-intensity aerobic exercise. Both absolute and relative FMD showed no main effects of trial or trial × time interactions, and the post-exercise changes relative to pre (ΔFMD) did not reach significance. Small-to-moderate effect sizes (e.g., partial η² ≈ 0.05-0.06 for interactions; ≈ 0.18-0.19 for time) and consistent directional tendencies suggest that subtle endothelial responses occurred over time, with no meaningful differences between trials. These results contradict our hypothesis, but provide a novel nutritional finding: combining a 7-day supplementation (10 mg/day) of piceatannol with low-intensity exercise shows limited effectiveness for the improvement of endothelial function, particularly in cases involving young, healthy men. Piceatannol has been proposed to enhance endothelial NO bioavailability through several mechanisms. It can activate eNOS and SIRT1, thereby supporting NO production [37]. It also bolsters antioxidant defenses, which limits superoxide and peroxynitrite and reduces NO scavenging [38]. Additionally, piceatannol can inhibit arginase, potentially increasing L-arginine availability for eNOS and improving endothelial function [39]. Acute and short-term polyphenol signals in humans are consistent with these mechanisms [8], but the magnitude and timing of endothelial engagement require sufficient molecular exposure and an adequate hemodynamic trigger. Short-term oral piceatannol undergoes extensive phase-II metabolism (glucuronidation, sulfation, O-methylation) and rapid clearance, with isorhapontigenin formation as a notable pathway [40,41]. These transformations reduce circulating parent compound and may alter endothelial target engagement. Without pharmacokinetic sampling in the present study, we cannot confirm systemic exposure. However, given the 10 mg/day dose for 7 days, plasma concentrations may have been below the level needed to activate eNOS-related signaling at the conduit artery. Future work should incorporate plasma piceatannol and key metabolite measurements. Moreover, we should test higher doses and/or longer durations to delineate exposure-response relationships and the contribution of metabolites to vascular effects. Endothelial adaptations are strongly shear-mediated. In the present study, although we found a significant main effect of time, low-intensity leg exercise did not produce a significant increase brachial artery shear rate and blood flow over time in post-hoc test. This result aligns with the previous study that reported low-intensity cycling exercise did not significantly increase brachial artery blood flow [42]. Thus, even if piceatannol primed endothelial signaling, the combined stimulus likely did not produce synergistic effects between exercise-induced shear stress and supplementation. This likely reflects the low exercise intensity. This study focused on low-intensity exercise with a view toward future application in individuals with low physical fitness. Nevertheless, it will be important to examine whether higher exercise intensities, within safe limits, can produce greater effects. In addition, participants in the present study were young, healthy men with baseline FMD in the normative range (placebo 7.7 ± 4.1%, piceatannol 8.6 ± 5.5%), which limits headroom for improvement [43]. Prior work suggests larger benefits of piceatannol in overweight men, whereas effects in normal weight men are small [19]. Our results align with this pattern and support a targeted supplementation approach. To our knowledge, this is the first study to examine the combined effects of piceatannol supplementation and aerobic exercise on endothelial function in humans, providing novel evidence despite the null findings. Future trials should recruit participants with suboptimal endothelial function, such as those with obesity, hypertension, insulin resistance, or older age. This study has several limitations. First, the sample size was modest, which widens confidence intervals and reduces power to detect small effects. The small sample may have amplified apparent between-subject variability in pre-exercise FMD (SD ≈ 5.5%). Accordingly, this study should be considered a pilot study, and larger, adequately powered trials are warranted. Moreover, male-only participation limits generalizability. Future studies should also enroll women and control for menstrual cycle phase to reduce hormonal variability and improve generalizability. Second, we did not measure biochemical mediators directly involved in endothelial function such as circulating nitrate/nitrite (NOx) [24], endothelin-1 [35], or angiotensin II [44] that are implicated in FMD and in exercise-/training-induced vascular adaptations. Third, background diet was controlled by verbal instructions (maintain usual diet; avoid other supplements), but we did not implement formal documentation or standardization. Future studies should include dietary records and, where feasible, standardized pre-assessment meals or nitrate/caffeine washouts to limit acute influences on shear, NO bioavailability, and vascular tone. Fourth, the intervention was short (7 days, 10 mg/day) with no pharmacokinetic sampling, precluding confirmation of systemic exposure to piceatannol and metabolites and optimal alignment of dosing with exercise. In summary, short-term, low-dose piceatannol combined with low-intensity aerobic exercise did not yield statistically significant improvements in endothelial function. However, the pattern of small effect sizes, the biochemical plausibility of endothelial engagement, and likely constraints related to exposure and shear thresholds suggest that the null findings reflect insufficient physiological drive rather than a lack of capacity for benefit. Future studies should test higher doses and longer durations with pharmacokinetic /metabolite profiling. Dosing should be aligned with exercise to increase temporal overlap between molecular availability and shear. Protocols that deliver moderate-to-high intensity or otherwise shear-rich stimuli are recommended. Trials should include participants with lower baseline endothelial function. Adding biochemical markers (e.g., NOx, endothelin-1, angiotensin II) and implementing dietary control will strengthen mechanistic attribution.